Five years ago, insulin prices were under such high pressure that Novo Nordisk had to downgrade its guidance multiple times, resulting in grave share price declines. The financial analyst Jefferies predicts Novo's growth engine with GLP-1 medication may encounter a similar type of pressure after 2023-24, when the patent for Novo Nordisk's first big seller in the GLP-1 series, Victoza, expires, according to Danish business daily Børsen.
"Our biggest worry is whether the price pressure, when Victoza generics are made accessible, will be transferred to the GLP-1 class or limited, since this is a daily treatment, and alleviated by the better-working Ozempic, or the more comfortable treatment Rybelsus," writes Jefferies Pharma & Biotech Research Analyst Peter Welford in a comment.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Ambu board had started headhunting process long before firing of CEO
Thursday’s CEO change had been in the works for a while, says Ambu’s board chair Jørgen Jensen.
Nine new drugs recommended for approval by CHMP at May meeting
During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.
Britt Meelby Jensen wants to rebuild trust in Ambu
After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.
Outgoing Ambu CEO commends colleagues
”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.
Top news from MedWatch this week
Miss anything?
Process Manager 
Biostatistician 
Clinical Project Manager 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Vice President, Test & Characterisation 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Communications Consultant 
Scientific Writer 
Cell Culture Scientist/Senior Scientist 
Account Manager 
SAP System Specialist (Product Supply) – Business Application Services 
Procurement Process Excellence Specialist 
Director Global Engineering 
Client Talent Acquisition Specialist 
(Senior) Drug Substance Specialist